
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
The American Journal of Managed Care
about 27 years ago
Is a Third-Trimester Antibody Screen in Rh+ Women Necessary?about 27 years ago
Drug Therapy of Allergic Rhinitisabout 27 years ago
Rethinking Formulary Strategy: Management and Measurement Considerations





